The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial-Reference-Cited by-同舟云学术

The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial

Published:2016-01-13 Issue:S1 Volume:87 Page:608-615
ISSN:1522-1946
Container-title:Catheterization and Cardiovascular Interventions
language:en
Short-container-title:Cathet. Cardiovasc. Intervent.

Author:

Liang Zhenyang¹,Li Yi¹,Wang Jingping²,Wang Dongmei³,Wang Shouli⁴,Ma Likun⁵,Liu Huiliang⁶,Yang Lixia⁷,Stone Gregg W.⁸,Han Yaling¹

Affiliation:

1. General Hospital of Shenyang Military Region; Shenyang Liaoning Province China

2. Shanxi Cardiovascular Hospital; Taiyuan Shanxi Province China

3. Shijiazhuang Peace Hospital; Shijiazhuang Hebei Province China

4. No. 306 Hospital of PLA, Beijing; Beijing City China

5. Anhui Provincial Hospital; Hefei Anhui Province China

6. Beijing CAPF General Hospital, Beijing; Beijing City China

7. Kunming General Hospital of Chengdu Military Region; Kunming Yunnan Province China

8. Columbia University Medical Center and the Cardiovascular Research Foundation; New York

Funder

the Chinese Government National Key R&D Project for the 12th Five-Year Plan

Salubris Pharmaceutical Co. (Shenzhen, China)

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ccd.26407/fullpdf

Reference33 articles.

1. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation;Steg;Eur Heart J,2012

2. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines;O'Gara;J Am Coll Cardiol,2013

3. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC);Hamm;Eur Heart J,2011

4. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Amsterdam;J Am Coll Cardiol,2014

5. Gender differences in the treatment for acute myocardial infarction: Bias or biology?;Anderson;Circulation,2007

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients;Experimental and Therapeutic Medicine;2023-09-27

2. Bivalirudin versus Heparin on Net Adverse Clinical Events, Major Adverse Cardiac and Cerebral Events, and Bleeding in Elderly Chinese Patients Treated with Percutaneous Coronary Intervention;The Tohoku Journal of Experimental Medicine;2023

3. Safety profile of bivalirudin in Chinese female patients undergoing percutaneous coronary intervention: a multi-center study;BMC Cardiovascular Disorders;2022-02-17

4. Sex Differences in Acute Bleeding and Vascular Complications Following Percutaneous Coronary Intervention Between 2003 and 2016: Trends From the Dartmouth Dynamic Registry;Cardiovascular Revascularization Medicine;2021-07

5. A meta‐analysis and cost‐minimization analysis of bivalirudin versus heparin in high‐risk patients for percutaneous coronary intervention;Pharmacology Research & Perspectives;2021-05